Calculus VCT – Now Open for Subscription

Calculus Capital launches VCT fundraising – providing exposure to a diverse portfolio of entrepreneurial growth companies Calculus Capital has launched a £10 million fundraising for the Calculus VCT, which aims to deliver investors an annual dividend of 4.5% and capital growth. … Continued

Calculus invests in Arecor

Calculus Capital has led a £6m funding round in Arecor, the UK-based biopharmaceutical formulation company, to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The funding also involved Albion Capital and Downing Ventures, with BioScience Managers Limited advising … Continued

Calculus invests £2m in Oxford BioTherapeutics

London, 3 August 2018: Calculus Capital has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised … Continued

Calculus invests £2m in CloudTrade

CloudTrade’s technology – which has been patented in Europe, the US and Australia – enables companies to automatically process electronic documents such as invoices and sales orders received by email. The software extracts information from a human-readable, machine-generated document, such … Continued

Calculus View on UK Industrial Strategy

The Prime Minister delivered a speech this week outlining the Government’s Industrial Strategy which aims to tackle the ‘Four Grand Challenges’ facing the world today, along with a target that UK R&D spend reaches 2.4% of GDP by 2027. The … Continued

Calculus completes a further investment in Mologic

Calculus Capital has completed a further investment into a growth capital investment round for Mologic alongside Foresight Group, who led the round. Mologic is a Point of Care (POC) diagnostics company that provides Contract Research (CRO) and manufacturing (CMO) services. … Continued